Norbert Hilf PhD

Norbert Hilf, Ph.D., is Vice President Translational Development of Immatics biotechnologies GmbH, a biotech company located in Germany and Texas dedicated to developing T-cell based immunotherapies against cancer. Dr. Hilf studied biochemistry, having received his doctoral degree in Biochemistry / Immunology from the University of Tuebingen, Germany working in the Department of Immunology headed by Hans-Georg Rammensee.
Dr. Hilf joined Immatics biotechnologies in 2004. Dr. Hilf’s department focuses on the translation of Immatics’ treatment modalities into early phase clinical development, including adoptive cellular therapies, bispecific T-cell receptors, and personalized vaccine approaches.